| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/27/2009 | EP2061798A2 Anti-tumor compounds for inhibiting cancer growth |
| 05/27/2009 | EP2061797A1 Therapeutic methods using wrn binding molecules |
| 05/27/2009 | EP2061796A2 Azetidine and azetidinone derivatives useful in treating pain and disorders of lipid metabolism |
| 05/27/2009 | EP2061795A2 Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof |
| 05/27/2009 | EP2061794A2 2-phenoxy pyrimidinone analogues |
| 05/27/2009 | EP2061793A2 Kw-3902 conjugates that do not cross the blood-brain barrier |
| 05/27/2009 | EP2061792A2 Azetidinone derivatives for the treatment of disorders of the lipid metabolism |
| 05/27/2009 | EP2061791A1 Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism |
| 05/27/2009 | EP2061790A1 Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them |
| 05/27/2009 | EP2061789A2 Thiadiazole compound and use thereof |
| 05/27/2009 | EP2061788A1 Novel compositions and methods for treatment of diseases related to activated lymphocytes |
| 05/27/2009 | EP2061786A2 Indazole derivatives as modulators of interleukin-1 receptor-associated kinase |
| 05/27/2009 | EP2061785A2 Linear pyridazine and pyrrole compounds, processes for obtaining them and uses |
| 05/27/2009 | EP2061782A1 Novel aminopyridine derivatives having aurora a selective inhibitory action |
| 05/27/2009 | EP2061780A1 Diaryl piperidine compounds as calcium channel blockers |
| 05/27/2009 | EP2061777A1 Benzoý1,2,3¨thiadiazine derivatives |
| 05/27/2009 | EP2061775A2 Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators |
| 05/27/2009 | EP2061774A2 Arylpiperazine derivatives and uses thereof |
| 05/27/2009 | EP2061773A2 Quinazoline based egfr inhibitors containing a zinc binding moiety |
| 05/27/2009 | EP2061771A1 Aspartyl protease inhibitors containing a tricyclic ring system |
| 05/27/2009 | EP2061769A1 Substituted benzimidazolone derivatives, medicaments comprising them and their use |
| 05/27/2009 | EP2061768A2 Imidazole-4,5-dicarboxamide derivatives as jak-2 modulators |
| 05/27/2009 | EP2061767A1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| 05/27/2009 | EP2061766A2 Novel compounds |
| 05/27/2009 | EP2061765A2 Serine-threonine protein kinase and parp modulators |
| 05/27/2009 | EP2061764A1 Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (pbr) |
| 05/27/2009 | EP2061762A2 Pyrazine compounds, their use and methods of preparation |
| 05/27/2009 | EP2061761A1 Phenethylamide derivatives with kinase inhibitory activity |
| 05/27/2009 | EP2061760A1 Benzo-fused compounds for use in treating metabolic disorders |
| 05/27/2009 | EP2061759A1 Cyclic modulators of chemokine receptor activity |
| 05/27/2009 | EP2061758A1 Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety |
| 05/27/2009 | EP2061757A2 Novel indole polymorphs |
| 05/27/2009 | EP2061756A2 2-aminocarbonylphenylamino-2-phenilacetamides as factor viia inhibitors useful as anticoagulants |
| 05/27/2009 | EP2061755A1 Tricyclic compounds useful in treating iron disorders |
| 05/27/2009 | EP2061754A1 Biaryl and biheteroaryl compounds useful in treating iron disorders |
| 05/27/2009 | EP2061751A1 Nitrate esters of aminoalcohols |
| 05/27/2009 | EP2061749A1 Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate |
| 05/27/2009 | EP2061743A1 Plants extracts for use in brain modulation |
| 05/27/2009 | EP2061561A1 Methods and compositions for treating cancer |
| 05/27/2009 | EP2061560A2 Bcl inhibitors for treating platelet excess |
| 05/27/2009 | EP2061484A2 Treatment, prevention, and reversal of alcohol-induced liver disease |
| 05/27/2009 | EP2061483A1 Oral polymeric membrane feruloyl esterase producing bacteria formulation |
| 05/27/2009 | EP2061482A1 Method of modulation of expression of epidermal growth factor receptor (egfr) involving mirna |
| 05/27/2009 | EP2061481A2 Cationic latex as a carrier for bioactive ingredients and methods for making and using the same |
| 05/27/2009 | EP2061480A2 Glms riboswitches, structure-based compound design with glms riboswitches, and methods and compositions for use of and with glms riboswitches |
| 05/27/2009 | EP2061479A2 Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
| 05/27/2009 | EP2061478A2 Sperm cell separation methods and compositions containing aptamers or nucleic acid sequences for use therein |
| 05/27/2009 | EP2061477A2 Compositions and methods for detection of lysosomal storage disease |
| 05/27/2009 | EP2061476A2 Compositions containing cdp-choline, and methods of use thereof |
| 05/27/2009 | EP2061475A2 Antisense composition and method for inhibition of mirna biogenesis |
| 05/27/2009 | EP2061474A2 Solid citrate and tartrate salts of dpp-iv inhibitors |
| 05/27/2009 | EP2061473A1 Increasing atp availability by inhibition of creatine kinase (ck) leakage resulting from high-intensity exercise |
| 05/27/2009 | EP2061472A2 Bacterial thioredoxin reductase inhibitors and methods for use thereof |
| 05/27/2009 | EP2061471A1 Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators |
| 05/27/2009 | EP2061470A2 Haloalkyl-substituted pyrimidinone derivatives |
| 05/27/2009 | EP2061469A2 Quinazoline based egfr inhibitors containing a zinc binding moiety |
| 05/27/2009 | EP2061468A2 Tyrosine kinase inhibitors containing a zinc binding moiety |
| 05/27/2009 | EP2061466A2 4-thio substituted quinoline and naphthyridine compounds |
| 05/27/2009 | EP2061465A2 Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| 05/27/2009 | EP2061464A2 Combination therapy for tumoral disease treatment |
| 05/27/2009 | EP2061463A1 Topical composition comprising a dihydropyridine calcium antagonist |
| 05/27/2009 | EP2061462A2 Treating pain, diabetes and lipid metabolism disorders |
| 05/27/2009 | EP2061461A2 3-azabicyclo[4.1.0]heptane derivatives for the treatment of depression |
| 05/27/2009 | EP2061460A2 2-aminobenzoxazole carboxamides as 5ht3 modulators |
| 05/27/2009 | EP2061459A2 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom |
| 05/27/2009 | EP2061458A1 Topiramate compositions and methods for their use |
| 05/27/2009 | EP2061457A1 Novel nutraceutical and pharmaceutical compositions and use thereof for the treatment, co-treatment or prevention of cartilage degradation or cartilage damage in joints |
| 05/27/2009 | EP2061456A2 Compositions and methods for inhibiting cytochrome p450 |
| 05/27/2009 | EP2061455A1 Stabilized synthetic brood pheromone for manipulating the behaviour and physiology of honey bees |
| 05/27/2009 | EP2061454A1 Compositions comprising a c2-c14 carboxylic acid and a surfactant for treating hoof diseases |
| 05/27/2009 | EP2061453A2 2,5-dihydroxybenzene compounds for treating cancers and hematological dyscrasias |
| 05/27/2009 | EP2061452A2 Anti cancer use of caffeic acid and derivatives |
| 05/27/2009 | EP2061451A2 Bis(thiohydrazide amides) for treating melanoma |
| 05/27/2009 | EP2061450A2 Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases |
| 05/27/2009 | EP2061449A1 Substituted acetylenic compounds useful for the treatment of diseases |
| 05/27/2009 | EP2061448A2 Sustained release formulation of naltrexone |
| 05/27/2009 | EP2061447A1 Compositions for the treatment of hoof diseases |
| 05/27/2009 | EP2061446A2 Use of cdk inhibitors for the treatment of granulocyte mediated disorders |
| 05/27/2009 | EP2061445A2 Antimicrobial compositions |
| 05/27/2009 | EP2061444A2 Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy |
| 05/27/2009 | EP2061442A2 Treatment, prevention, and reversal of alcohol-induced brain disease |
| 05/27/2009 | EP2061441A2 Transdermal delivery of meptazinol |
| 05/27/2009 | EP2061440A2 A pharmaceutical composition of tacrolimus |
| 05/27/2009 | EP2061439A1 Pharmaceutical composition comprising a plurality of mini-tablets comprising a factor xa inhibitor |
| 05/27/2009 | EP2061438A1 Extended release gastro-retentive oral drug delivery system for valsartan |
| 05/27/2009 | EP2061437A1 Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
| 05/27/2009 | EP2061436A1 Ibuprofen-effervescent preparation having a high dissolution rate and method for the production thereof |
| 05/27/2009 | EP2061435A2 Polystyrene sulfonate polymer tablets, their preparation and use |
| 05/27/2009 | EP2061433A2 Compositions and methods for enhancing transport through mucus |
| 05/27/2009 | EP2061432A1 Nano-vehicle for the transcutaneous transport, preparation containing the same and its use |
| 05/27/2009 | EP2061430A2 Bis (thiohydrazide amides) formulation |
| 05/27/2009 | EP2061429A2 Method of treating bone cancer |
| 05/27/2009 | EP2061347A2 USE OF DPA(n-6) OILS IN INFANT FORMULA |
| 05/27/2009 | EP2061346A1 Non-allergenic ingredients and food products |
| 05/27/2009 | EP2061341A1 Food supplementation composition containing one or more vitamin d3 compounds and one or more magnesium salts |
| 05/27/2009 | EP2061322A2 Pharmacokinetically improved compounds |
| 05/27/2009 | EP2061316A2 Azole nucleosides and use as inhibitors of rna and dna varial polymerases |
| 05/27/2009 | EP2061315A2 Tonsillitis treatment |
| 05/27/2009 | EP2061314A2 Compounds for improving learning and memory |
| 05/27/2009 | EP2061309A2 Compositions and methods of use thereof for the removal of ticks from epidermal tissue |